CCO - Translational Medicine
Anthony E. Maida, III, Ph.D., MA, MBA, BA, BA
Dr. Maida is currently Chief Clinical Officer – Translational Medicine, focused on the immunotherapy of cancers and infectious disease. Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., (9 years) a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. He was responsible for the oversight of the operations of the Company. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 25 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer. Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities. He is an expert in ‘virtual’ development and cost-cutting of operations in large and small biotechnology companies. Dr. Maida has negotiated licensing agreements with a number of centers of excellence and premier pharmaceutical firms including but not limited to Eli Lilly, Novartis, RCT Corporation, Astra Zeneca, Pfizer, MD Anderson, Yale University, Stanford University, University of California San Francisco and Davis, the Wistar Institute, and Bristol Myers Squibb to mention a few. Over the past 18 years Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida was formerly the President and CEO of Replicon NeuroTherapeutics, Inc., a biopharmaceutical company focused on the therapy of patients with tumors (both primary and metastatic) of the CNS where he raised $3 million and was responsible for all financial and operational aspects of the Company. Prior to Replicon Dr. Maida served as Interim CEO for Trellis Bioscience, Inc. where he was responsible for securing the Company’s first round of financing ($7 million). In 2000 Dr. Maida served as President of CancerVax Corporation where he raised the Company’s first round of financing in the amount of $30 million. Over recent years Dr. Maida has raised, or assisted in financings, in excess of $200 million for start-up and emerging biotechnology companies. From 1992 to September of 1999, Dr. Maida was President and Chief Executive Officer of Jenner Biotherapies, Inc. During his tenure at Jenner, Dr. Maida ushered four (4) products into the clinic; one Phase III randomized clinical trial demonstrating clinical benefit to patients with osteogenic sarcoma which ultimately gained approval in Europe, two (2) Phase II double-blinded randomized placebo controlled clinical trials in patients with prostate cancer and nine (9) Phase I/II clinical trials. Prior to Jenner Biotherapies, Dr. Maida served as Vice President of Finance and CFO for Lockheed DataPlan, a wholly owned subsidiary, and Senior Financial Controller of Lockheed Missiles, a $1.7 billion division, of Lockheed Missiles and Space Company. Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc. Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat as a board member and Audit Chair of Vitality BioPharma, Inc. (NASDAQ:VBIO), Inc., Innovate Pharma (NASDAQ:INNT), OncosSec Medical, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 14 years, Sirion Therapeutics, Inc., and GlycoMetrix, Inc. Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.
